ERBB2 and cervical adenocarcinoma: Further investigation of more HER2‐amplified cases and GAC with longer follow‐up time is required to develop more precise evaluation criteria for HER2 detection and to clarify the clinical significance of HER2 amplification in cervical adenocarcinomas.